A prospective open-label trial compared the effects of denosumab and zoledronate on CD14+CD11b+ cells and CD14+CD11b+VNR+ cells over 48 weeks in postmenopausal women with osteoporosis (46). This evidence concerns the gene ITGAM and osteoporosis.